BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 26595058)

  • 1. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.
    Paul S; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
    Ann Intern Med; 2016 Jan; 164(1):30-40. PubMed ID: 26595058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
    Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis.
    Cheung CKM; Law MF; Chao DC; Wong SH; Ho R; Chao ACW; Lai JWY; Chan TYT; Tam MTK; Lau SLF; Tam THC
    J Dig Dis; 2020 Mar; 21(3):160-169. PubMed ID: 32040243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
    Wu YT; Li X; Liu ZL; Xu Z; Dai W; Zhang K; Wu JS; Arshad B; Wu KN; Kong LQ
    PLoS One; 2017; 12(6):e0179680. PubMed ID: 28640902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
    Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
    Loomba R; Rowley A; Wesley R; Liang TJ; Hoofnagle JH; Pucino F; Csako G
    Ann Intern Med; 2008 Apr; 148(7):519-28. PubMed ID: 18378948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.
    Chen CY; Tien FM; Cheng A; Huang SY; Chou WC; Yao M; Tang JL; Tien HF; Sheng WH
    BMC Gastroenterol; 2018 Jan; 18(1):6. PubMed ID: 29310589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
    Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
    Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.
    Xu Z; Dai W; Wu YT; Arshad B; Li X; Wu H; Chen HR; Wu KN; Kong LQ
    Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12799. PubMed ID: 29265535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.
    Paul S; Dickstein A; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
    Hepatology; 2017 Aug; 66(2):379-388. PubMed ID: 28128861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.
    Ding ZN; Meng GX; Xue JS; Yan LJ; Liu H; Yan YC; Chen ZQ; Hong JG; Wang DX; Dong ZR; Li T
    J Cancer Res Clin Oncol; 2023 May; 149(5):1993-2008. PubMed ID: 35767193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
    Kohrt HE; Ouyang DL; Keeffe EB
    Clin Liver Dis; 2007 Nov; 11(4):965-91, x. PubMed ID: 17981237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
    Liu S; He Z; Wu W; Jin H; Cui Y
    Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
    Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
    J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
    Su J; Long L; Zou K
    Clin Rheumatol; 2018 Dec; 37(12):3201-3214. PubMed ID: 29637482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
    Li P; Zhou L; Ye S; Zhang W; Wang J; Tang X; Liu J; Xu Y; Qian W; Liang A
    Front Immunol; 2021; 12():638678. PubMed ID: 34335561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.
    Lv JW; Chen YP; Huang XD; Zhou GQ; Chen L; Li WF; Tang LL; Mao YP; Guo Y; Xu RH; Ma J; Sun Y
    Cancer; 2017 Sep; 123(18):3540-3549. PubMed ID: 28493307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.